Abstract
Peripheral blood hematopoietic progenitor cells (PBHC) are the standard source of support for high-dose chemotherapy because of faster recovery of marrow function. Unfortunately, a proportion of patients are unable to mobilize adequate progenitors to proceed to autologous hematopoietic cell transplant (AHCT). Granulocyte-CSF-stimulated BM-derived hematopoietic progenitor cells (BMHC) may circumvent this problem. From 1999 to 2006, 52 patients (cases) with AML, Hodgkin (HL) or non-Hodgkin's lymphoma (NHL) in whom PBHC mobilization failed underwent a G-CSF-stimulated bone marrow harvest and proceeded to AHCT. Their outcome was compared with 422 patients (controls) with AML, HL and NHL undergoing AHCT using only PBHC. Twenty-three patients received BMHC alone and 29 patients recieved a combination of PBHC and BMHC. Median engraftment time for neutrophils (>0.5 × 109/l) and platelets (>20 × 109/l) were 14 and 27 days, but significantly longer when compared with controls (11days, 11 days, P<0.0001). Patients receiving both PBHC and BMHC had faster engraftment, when compared with those receiving BMHC alone (P<0.001). In conclusion, performing an AHCT using G-CSF-stimulated BMHC in patients failing PBHC collection is feasible with faster engraftment seen in patients receiving both BMHC and PBHC over BMHC alone.
| Original language | English |
|---|---|
| Pages (from-to) | 733-737 |
| Number of pages | 5 |
| Journal | Bone Marrow Transplantation |
| Volume | 42 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 2008 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation. / Seshadri, T.; Al-Farsi, K.; Stakiw, J.; Ma, C.; Saragosa, R.; Franke, N.; Keating, A.; Crump, M.; Kuruvilla, J.
In: Bone Marrow Transplantation, Vol. 42, No. 11, 2008, p. 733-737.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation
AU - Seshadri, T.
AU - Al-Farsi, K.
AU - Stakiw, J.
AU - Ma, C.
AU - Saragosa, R.
AU - Franke, N.
AU - Keating, A.
AU - Crump, M.
AU - Kuruvilla, J.
PY - 2008
Y1 - 2008
N2 - Peripheral blood hematopoietic progenitor cells (PBHC) are the standard source of support for high-dose chemotherapy because of faster recovery of marrow function. Unfortunately, a proportion of patients are unable to mobilize adequate progenitors to proceed to autologous hematopoietic cell transplant (AHCT). Granulocyte-CSF-stimulated BM-derived hematopoietic progenitor cells (BMHC) may circumvent this problem. From 1999 to 2006, 52 patients (cases) with AML, Hodgkin (HL) or non-Hodgkin's lymphoma (NHL) in whom PBHC mobilization failed underwent a G-CSF-stimulated bone marrow harvest and proceeded to AHCT. Their outcome was compared with 422 patients (controls) with AML, HL and NHL undergoing AHCT using only PBHC. Twenty-three patients received BMHC alone and 29 patients recieved a combination of PBHC and BMHC. Median engraftment time for neutrophils (>0.5 × 109/l) and platelets (>20 × 109/l) were 14 and 27 days, but significantly longer when compared with controls (11days, 11 days, P<0.0001). Patients receiving both PBHC and BMHC had faster engraftment, when compared with those receiving BMHC alone (P<0.001). In conclusion, performing an AHCT using G-CSF-stimulated BMHC in patients failing PBHC collection is feasible with faster engraftment seen in patients receiving both BMHC and PBHC over BMHC alone.
AB - Peripheral blood hematopoietic progenitor cells (PBHC) are the standard source of support for high-dose chemotherapy because of faster recovery of marrow function. Unfortunately, a proportion of patients are unable to mobilize adequate progenitors to proceed to autologous hematopoietic cell transplant (AHCT). Granulocyte-CSF-stimulated BM-derived hematopoietic progenitor cells (BMHC) may circumvent this problem. From 1999 to 2006, 52 patients (cases) with AML, Hodgkin (HL) or non-Hodgkin's lymphoma (NHL) in whom PBHC mobilization failed underwent a G-CSF-stimulated bone marrow harvest and proceeded to AHCT. Their outcome was compared with 422 patients (controls) with AML, HL and NHL undergoing AHCT using only PBHC. Twenty-three patients received BMHC alone and 29 patients recieved a combination of PBHC and BMHC. Median engraftment time for neutrophils (>0.5 × 109/l) and platelets (>20 × 109/l) were 14 and 27 days, but significantly longer when compared with controls (11days, 11 days, P<0.0001). Patients receiving both PBHC and BMHC had faster engraftment, when compared with those receiving BMHC alone (P<0.001). In conclusion, performing an AHCT using G-CSF-stimulated BMHC in patients failing PBHC collection is feasible with faster engraftment seen in patients receiving both BMHC and PBHC over BMHC alone.
UR - http://www.scopus.com/inward/record.url?scp=58149473086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149473086&partnerID=8YFLogxK
U2 - 10.1038/bmt.2008.249
DO - 10.1038/bmt.2008.249
M3 - Article
VL - 42
SP - 733
EP - 737
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 11
ER -